Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
Top Cited Papers
- 28 August 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9798), 1231-1243
- https://doi.org/10.1016/s0140-6736(11)61215-4
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing WorldPLoS Medicine, 2010
- Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI dataBMC Cardiovascular Disorders, 2010
- The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countriesAmerican Heart Journal, 2009
- Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countriesThe Lancet, 2009
- Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry dataThe Lancet, 2008
- Adherence to MedicationNew England Journal of Medicine, 2005
- What Is Community? An Evidence-Based Definition for Participatory Public HealthAmerican Journal of Public Health, 2001
- Global Burden of Cardiovascular DiseasesCell Metabolism, 2001
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985